Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study (I-Profile)

This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:

1. CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy.
2. CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery.
3. There are trimester-specific glucose profiles observed in the whole pregnancy.
4. Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal).
5. There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening.
6. Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.

Study Overview

• Status: Completed
• Conditions: Pregnancy; Gestational Diabetes
• Intervention / Treatment: Device: Blinded Group; Device: Unblinded group

Detailed Description

GDM affects 5-10% of pregnant women in Europe, while the prevalence in Asian populations is significantly higher at approximately 15-20%. However, the GDM screening approaches, timing and targeted population still varies greatly in clinical practice all over the world, which makes the prevalence of GDM difficult to compare universally. Since the early days of the 21st century, the continuous glucose monitoring system (CGM) has been used for constant evaluation of glucose levels by measuring interstitial glucose concentrations. It can potentially improve diabetes care if used carefully with proper understanding of the characteristics of this system.

This is longitudinal, observational and hospital-based study. A total of 500 pregnant women will be recruited with consent form completion after meeting our inclusion criteria. The recruited women will then be randomly assigned to a Blinded and Unblinded CGM device.

All pregnant women aged 21 and above who plan to be followed up throughout pregnancy and intend to deliver at KKH and currently attending KKH for antenatal consultation during their early trimester will be approached by study research personnel, and will be followed up from then onwards. If they agree to take part in the study, consent will be signed at the first trimester clinic visit.

All recruited subjects will be randomized to put on a Blinded or Unblinded CGM device for 14 days from the first trimester (9-13 weeks), 18-23 weeks, 24-31 weeks, and 32-33 weeks. If a pregnant subject is diagnosed with GDM using International association of diabetes and pregnancy study groups (IADPSG) guidelines at KKH at 24-31 weeks gestation, she will be required to wear the sensor continuously until 38 weeks gestation, and will be followed up for another 14 days at the 6-12 weeks postnatal period.

Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, medical histories, lifestyle factors, health status, and home environment. Bio-physical measurements will be obtained from anthropometric measurements of participants, human biological materials such as blood, are collected from the participants at their follow-up time points with the I-PROFILE study upon their consent.

• Study Type: Interventional
• Enrollment (Actual): 240
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Singapore
  • Singapore, Singapore, 229899
    • KK Women's and Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH;
2. Aged 21 and above;
3. Singleton pregnancy

Exclusion Criteria:

1. Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days;
2. Patients who have any other chronic disease such as chronic kidney disease.
3. Unable to read or speak English

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Blinded Group; Participants in the blinded group will be wearing the sensor for 14 days without a reader. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.	Device: Blinded Group; Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
Experimental: Unblinded Group; Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.	Device: Unblinded group; Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gestational Diabetes Mellitus (GDM)	Clinical outcomes of Gestational Diabetes Mellitus (GDM) development determined by oral glucose tolerance test	24-31 weeks gestation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CGM summary metrics derived from extracted CGM glucose data	Glucose profiles extracted from the continous glucose monitoring (CGM) device	First trimester: 9-13 weeks, Second trimester: 18-23 weeks, 24-31 weeks, 32-33 weeks
Plasma glucose measures from OGTT	Fasting, one hour and 2 hour glucose values obtained from OGTT	24-31 weeks gestation

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Applicability, acceptability, compliance of the blinded the CGM device use in a normal pregnancy.	Using a 10-item patient feedback survey	At 32-33 weeks gestation
Applicability, acceptability, compliance of the unblinded the CGM device use in a normal pregnancy.	Using a 14-item patient feedback survey	At 32-33 weeks gestation
Applicability, acceptability, compliance of the blinded CGM device use in a GDM pregnancy	Using 10-item patient feedback survey	6-12 weeks postnatal
Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy	Using a 14-item patient feedback survey	6-12 weeks postnatal

Collaborators and Investigators

• Sponsor: KK Women's and Children's Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 16, 2018
• Primary Completion (Actual): August 31, 2024
• Study Completion (Actual): August 31, 2024

Study Registration Dates

• First Submitted: October 25, 2021
• First Submitted That Met QC Criteria: November 16, 2021
• First Posted (Actual): November 17, 2021

Study Record Updates

• Last Update Posted (Actual): October 10, 2024
• Last Update Submitted That Met QC Criteria: October 9, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Diabetes, Gestational
• Other Study ID Numbers: 2018/2128

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes